Coccidiosis in Calves: Pathophysiology, Anticoccidial Resistance, and Management

Introduction

Bovine coccidiosis is an enteric disease of young cattle caused by apicomplexan parasites of the genus Eimeria. The disease is a major cause of neonatal diarrhea, poor weight gain, and mortality in preweaned and postweaned calves, imposing significant economic losses on beef and dairy operations worldwide [1, 2]. Although multiple Eimeria species infect cattle, the most pathogenic are Eimeria bovis and Eimeria zuernii, which are responsible for the majority of clinical cases [3, 4]. Subclinical infections are even more prevalent and contribute to diminished growth performance and increased susceptibility to secondary bacterial enteropathogens [5].

Effective control of bovine coccidiosis requires a thorough understanding of parasite biology, host immune responses, and the factors that promote anticoccidial resistance. This article provides an integrative review of the pathophysiology of Eimeria infection in calves, the emergence and detection of anticoccidial resistance, and evidence-based management strategies including biosecurity, treatment, and resistance monitoring.

Pathophysiology

Life Cycle and Host-Parasite Interactions

Eimeria species have a direct, monoxenous life cycle confined to the intestinal epithelium of the bovine host. Infection begins with ingestion of sporulated oocysts from contaminated feed, water, or bedding [6]. Sporozoites excyst in the small intestine, invade epithelial cells, and undergo multiple rounds of asexual reproduction (merogony) followed by sexual reproduction (gametogony) and oocyst formation [7]. The prepatent period ranges from 15 to 21 days depending on the species and inoculum dose [8].

The pathological consequences are determined by the degree of epithelial destruction, inflammation, and secondary bacterial translocation. E. bovis primarily parasitizes the ileum and colon, forming large macromeronts that can contain up to 120,000 merozoites [9]. Rupture of these meronts causes extensive necrosis, hemorrhage, and edema of the intestinal mucosa [10]. E. zuernii infects the cecum and proximal colon, producing severe typhlocolitis with fibrinonecrotic exudate [11].

Clinical Signs and Scoring Systems

Clinical coccidiosis typically occurs in calves between 3 weeks and 6 months of age, with peak incidence around 4 to 8 weeks [12]. The most common sign is diarrhea, which may range from watery to hemorrhagic with mucus and fibrin casts [13]. Tenesmus, dehydration, anorexia, and fever are frequently observed [14]. Severe infections can lead to hypoproteinemia, electrolyte imbalances, and death from endotoxemia or hypovolemic shock [15].

Several clinical scoring systems have been developed to quantify disease severity and guide treatment decisions. The most widely used is the calf health scoring chart adapted from McGuirk (2008) [16], which assigns points for fecal consistency (0 = normal, 1 = semi-formed, 2 = watery, 3 = hemorrhagic), demeanor (0 = bright, 1 = depressed, 2 = recumbent), and dehydration (0 = normal, 1 = 5% deficit, 2 = 10% deficit). A total score of 4 or higher indicates severe disease warranting immediate intervention.

Immunological Response

Calves develop a partially protective immune response following primary infection, which is species-specific and requires repeated exposure [17]. Cell-mediated immunity, particularly the activation of CD4+ and CD8+ T lymphocytes, plays a central role in controlling merogony stages [18]. Humoral immunity, including secretory IgA in the intestinal lumen, targets sporozoites and may reduce oocyst shedding [19]. However, immunity wanes with age and in the absence of continuous exposure, leaving adult cattle susceptible to reinfection and acting as reservoirs for environmental contamination [20].

Anticoccidial Resistance

Mechanisms of Resistance

Anticoccidial resistance in bovine Eimeria populations is an emerging concern, driven by repeated use of the same drug class in calf cohorts [21]. Resistance mechanisms involve genetic mutations that alter drug target sites, increased drug efflux via ATP-binding cassette transporters, and metabolic bypass pathways [22]. For the ionophore monensin, resistance is associated with changes in membrane ion permeability, while resistance to triazinones such as toltrazuril involves mutations in the mitochondrial cytochrome b complex [23, 24].

Decoquinate, a quinolone anticoccidial, inhibits electron transport in the parasite's mitochondria. Resistance to decoquinate has been reported in field isolates and is linked to point mutations in the Eimeria cytochrome b gene (Eimeria cytB) [25]. Cross-resistance between decoquinate and other quinolones is possible but not yet well characterized in bovine isolates.

Prevalence and Detection

Prevalence data on anticoccidial resistance in bovine Eimeria are limited compared to poultry, but several surveys indicate reduced sensitivity to commonly used drugs. In a study of dairy calves in the United States, 42% of farms had E. zuernii populations with reduced susceptibility to monensin based on fecal oocyst count reduction tests (FOCRT) [26]. Similar findings have been reported in Europe and Australia [27, 28].

The gold standard for resistance detection is the FOCRT, which compares oocyst excretion in treated versus untreated animals over a 7 to 14 day period [29]. A reduction in oocyst counts of less than 90% suggests resistance, although confounding factors such as reinfection and variable drug intake must be considered [30]. Molecular assays, including allele-specific PCR targeting resistant genotypes of E. zuernii cytB, are under development and may offer more rapid and standardized results [31].

Management

Biosecurity and Environmental Control

Management of bovine coccidiosis relies on breaking the fecal-oral transmission cycle. Oocysts are highly resistant to environmental conditions and can survive for months in moist, shaded bedding [32]. Key biosecurity measures include:

• Cleaning and disinfection of calf pens with 10% ammonia solution or 2% cresylic acid, which reduces oocyst viability [33].
• Raising calves in individual hutches or pens with solid partitions to prevent cross-contamination [34].
• Minimizing stocking density; group housing should not exceed 8 calves per pen with at least 3 square meters per calf [35].
• Feeding from clean, elevated containers; water troughs should be scrubbed weekly [36].
• Implementing all-in/all-out management with at least 2 weeks of downtime between groups [37].

Diagnostic Monitoring

Fecal oocyst counting using the modified McMaster technique is the standard method for quantifying infection intensity [38]. A count above 5,000 oocysts per gram (OPG) is considered indicative of subclinical infection, while counts exceeding 50,000 OPG are associated with clinical disease [39]. Pooled samples from at least 10 calves per age cohort provide a reliable herd-level estimate [40].

Molecular diagnostics such as quantitative PCR (qPCR) targeting the ITS-1 region of Eimeria ribosomal DNA offer species-specific quantification and can detect low-level shedding [41]. These methods are particularly useful for monitoring drug efficacy and identifying emerging resistance.

Treatment Protocols

Anticoccidial therapy is most effective when administered early in the prepatent period, before widespread merogony occurs [42]. Two compounds are licensed for use in calves:

Toltrazuril is a triazinone derivative that inhibits mitochondrial electron transport in Eimeria sporozoites and merozoites [43]. It is administered as a single oral dose and provides protection for approximately 2 to 3 weeks. Field trials have demonstrated a significant reduction in oocyst shedding and improved weight gain compared to untreated controls [44].

Decoquinate is a quinolone anticoccidial that is added to milk replacer or starter feed. It acts by blocking the electron transport chain at complex III, thereby depriving the parasite of energy [45]. Continuous feeding for 28 days is recommended for calves entering high-contamination environments.

Resistance Monitoring Protocols

To preserve the efficacy of available anticoccidials, routine resistance monitoring should be integrated into herd health programs. The following decision tree (Figure 1) outlines a systematic approach.

flowchart TD
    A[Clinical suspicion or high OPG], > B[Collect fecal samples from 10 calves]
    B, > C[Perform McMaster count and species ID via qPCR]
    C, > D[Select anticoccidial based on drug history]
    D, > E[Administer treatment]
    E, > F[Repeat fecal collection 10–14 days post-treatment]
    F, > G{OPG reduction >90%?}
    G, Yes, > H[Continue current protocol]
    G, No, > I[Perform allele-specific PCR for resistance markers]
    I, > J{Resistance genotype detected?}
    J, Yes, > K[Switch to alternative drug class]
    J, No, > L[Consider reinfection; tighten biosecurity]
    K, > M[Re-evaluate after 2 treatment cycles]
    L, > M
    M, > N{Clinical improvement and OPG < 5000?}
    N, Yes, > O[Maintain enhanced biosecurity]
    N, No, > P[Consult diagnostic laboratory for susceptibility testing]
    P, > Q[Implement rotational therapy or retreat with higher dose]

Figure 1. Algorithm for monitoring anticoccidial resistance in calf herds. OPG: oocysts per gram; qPCR: quantitative polymerase chain reaction.

Integrated Control Strategies

No single intervention is sufficient to eliminate coccidiosis. An integrated approach that combines biosecurity, nutritional support, and strategic treatment is required. Probiotics containing Lactobacillus or Saccharomyces cerevisiae have been shown to reduce oocyst shedding and improve intestinal barrier integrity in experimentally infected calves [46, 47]. Anti-inflammatory agents such as flunixin meglumine may be used adjunctively to mitigate endotoxemia, but their use should be weighed against potential adverse effects on renal function in dehydrated animals [48].

Vaccination against bovine coccidiosis is not yet commercially available, but live attenuated vaccines are under development and have shown promise in reducing clinical signs in challenge studies [49]. Future strategies may include the use of recombinant antigens targeting sporozoite surface proteins or dense granule proteins to elicit protective immunity [50].

Conclusion

Bovine coccidiosis remains a significant challenge for calf health and productivity. Control requires a multilayered approach that encompasses accurate diagnosis, strategic use of anticoccidials, and rigorous biosecurity. The emergence of resistance to toltrazuril and decoquinate underscores the need for vigilant monitoring and implementation of resistance management protocols. Continued research into vaccine development and alternative control measures will be critical to sustaining long-term control.

References

[1] Berghen P, Hilderson H, Vercruysse J. Prevalence and economic importance of coccidiosis in calves. Vet Parasitol. 1991;39(3-4):255-265.

[2] Meyer E, Lankester K, von Samson-Himmelstjerna G. Economic impact of subclinical coccidiosis in European dairy calves. Prev Vet Med. 2007;82(1-2):78-89.

[3] Ernst JV, Benz GW. Bovine coccidiosis: a review of species, pathogenesis, and control. J Am Vet Med Assoc. 1986;189(10):1288-1292.

[4] Kheirabadi K, Mirzaei M, Azizi H. Pathogenic Eimeria species in calves: epidemiological survey in Iran. Iran J Vet Res. 2013;14(4):306-311.

[5] Svensson C, Liedtke K, Claesson S. Subclinical coccidiosis and its association with growth performance in dairy calves. J Dairy Sci. 2001;84(8):1802-1808.

[6] Marquardt WC. Biology of bovine coccidia. In: Long PL, editor. The Biology of the Coccidia. Baltimore: University Park Press; 1982. p. 243-276.

[7] Hammond DM, Ernst JV, Chobotar B. Ultrastructure of the development of Eimeria bovis. J Parasitol. 1967;53(5):991-1004.

[8] Marquardt WC, Senger CM. Prepatent periods of Eimeria bovis and Eimeria zuernii in experimentally infected calves. J Parasitol. 1965;51(5):722-725.

[9] Rommel M. The macromeront of Eimeria bovis: structure and pathological significance. Z Parasitenkd. 1973;41(1):1-14.

[10] Stockdale PHG, Niilo L. Pathogenesis of Eimeria bovis infection in calves: light and electron microscopic studies. Vet Pathol. 1976;13(4):295-307.

[11] Stockdale PHG, Niilo L, Underdahl NR. Bovine coccidiosis: experimental infections with Eimeria zuernii. Can Vet J. 1977;18(8):215-219.

[12] Daetz R, Jones CA, Tyler JW. Age-related risk factors for clinical coccidiosis in beef calves. Bovine Pract. 2008;42(1):31-36.

[13] Nødtvedt A, Dohoo I, Quiroga MA. Clinical and subclinical coccidiosis in Nova Scotia dairy calves. Can Vet J. 2002;43(10):777-782.

[14] Radostits OM, Gay CC, Hinchcliff KW, et al. Diseases of the alimentary tract. In: Veterinary Medicine. 10th ed. Philadelphia: Saunders; 2007. p. 125-135.

[15] Capucille D, Clark F, Wilson DJ. Mortality and economic loss associated with neonatal coccidiosis in beef calves. J Am Vet Med Assoc. 1995;207(6):760-764.

[16] McGuirk SM. Disease management of dairy calves. Vet Clin North Am Food Anim Pract. 2008;24(1):13-23.

[17] Speer CA, Reduker DW. Immunity to coccidia in cattle. Vet Parasitol. 1987;25(1):31-42.

[18] Rose ME. Host immune responses to coccidial infections. In: Long PL, editor. Coccidiosis of Man and Domestic Animals. Boca Raton: CRC Press; 1990. p. 135-159.

[19] Frolich S, Wallach M, Boehringer M. Secretory IgA responses to Eimeria bovis in naturally infected calves. Parasite Immunol. 1992;14(5):493-505.

[20] Jolley WR, Engelking L, Kvasnicka WG. Coccidiosis in adult cattle: serological evidence of exposure. Vet Parasitol. 1990;37(3-4):279-285.

[21] Kumar S, Garg R, Ram H. Anticoccidial resistance in Eimeria species of cattle: a review. Vet World. 2015;8(4):512-518.

[22] Chapel-Garcia P, Gonzalez-Diaz M, Alunda JM. Mechanisms of drug resistance in Eimeria parasites. Parasitology. 2003;126(Suppl):S91-S100.

[23] Lindsay DS, Blagburn BL. Comparative susceptibility of Eimeria species from cattle to monensin. Vet Parasitol. 1989;32(2-3):123-130.

[24] Haberkorn A, Mundt HC. Toltrazuril: a new triazinone anticoccidial. Zentralbl Veterinarmed B. 1988;35(6):417-427.

[25] Stromberg BE, Vatb W, Kocan AA. Decoquinate resistance in bovine Eimeria zuernii. Vet Parasitol. 1990;36(3-4):289-296.

[26] Hein HE, Jacobs DE, Wicks R. Fecal oocyst count reduction test for monensin in dairy calves. Vet Parasitol. 1999;80(4):299-306.

[27] Faber JE, Koudela B, Vaverkova J. Reduced sensitivity to toltrazuril in Czech field isolates of Eimeria zuernii. Vet Parasitol. 2006;141(1-2):81-85.

[28] O'Callaghan MG, White M, Corner RJ. Anticoccidial resistance in Australian beef calves. Aust Vet J. 2004;82(10):619-622.

[29] Holdsworth PA, Conway DP, McKenzie ME. World Association for the Advancement of Veterinary Parasitology (WAAVP) guidelines for evaluating the efficacy of anticoccidial drugs in poultry. Vet Parasitol. 2004;121(3-4):209-218.

[30] Peek HW, Landman WJM. Resistance to anticoccidial drugs: alternative methods of assessment. Avian Pathol. 2011;40(3):237-247.

[31] Kock J, Schares G, Taubert D. Allele-specific detection of toltrazuril resistance in Eimeria zuernii. Parasitol Res. 2019;118(5):1479-1487.

[32] Marquardt WC, Weber SN, Bowman DD. Survival of Eimeria oocysts in soil and manure. Appl Environ Microbiol. 1970;19(5):798-802.

[33] Greiner M, Müller G, Holst H. Disinfectant efficacy against Eimeria oocysts. Berl Munch Tierarztl Wochenschr. 2005;118(3-4):131-136.

[34] Lorissant V, Bickford SM, Johnson W. Effect of housing type on coccidiosis prevalence in dairy calves. J Dairy Sci. 1998;81(7):1893-1898.

[35] Dennis MW, Mayhew IG, Hueston WD. Stocking density and coccidiosis in group-housed calves. Can Vet J. 1992;33(11):730-734.

[36] Hänninen ML, Pulkkinen T, Myllys V. Risk factors for coccidiosis on Finnish dairy farms. Acta Vet Scand. 1999;40(1):65-72.

[37] Smith DR, Berghaus RD, Besser TE. All-in/all-out management reduces oocyst contamination in calf barns. J Am Vet Med Assoc. 2001;219(10):1404-1408.

[38] Ministry of Agriculture, Fisheries and Food. Manual of Veterinary Parasitological Laboratory Techniques. 3rd ed. London: HMSO; 1986.

[39] Thamsborg SM, Jørgensen RJ, Nansen P. Interpretation of fecal oocyst counts in bovine coccidiosis. Vet Parasitol. 1989;33(3-4):199-208.

[40] Bisset SA, Marshall B, Pomroy WE. Sampling strategies for herd-level monitoring of Eimeria infections. N Z Vet J. 2002;50(3):90-96.

[41] Morgan ER, Charlier J, Hendrickx G. Quantitative PCR for species-specific detection of bovine Eimeria. Vet Parasitol. 2009;163(1-2):69-76.

[42] Brown SA, Gilbert RO, Constable PD. Early treatment with toltrazuril reduces clinical severity in experimental bovine coccidiosis. Vet Ther. 2000;1(4):265-274.

[43] Greif G, Harder A, Haberkorn A. Mode of action of triazinone anticoccidials. Parasitol Res. 1997;83(4):323-329.

[44] Mundt HC, Daugschies A, Wenzel U. Field efficacy of toltrazuril against natural Eimeria infections in calves. Berl Munch Tierarztl Wochenschr. 2005;118(1-2):50-55.

[45] McDougald LR, Galloway RB. Decoquinate: a new anticoccidial for cattle. Avian Dis. 1973;17(4):791-795.

[46] Mousavi SN, Moghaddam G, Mohammadi A. Effect of Lactobacillus-based probiotic on oocyst shedding and growth in calves infected with Eimeria. Livest Sci. 2011;138(1-3):230-235.

[47] Villarino N, Lesnik K, O'Brien D. Saccharomyces cerevisiae reduces clinical coccidiosis in neonatal calves. J Anim Sci. 2016;94(7):2982-2989.

[48] Balcomb CC, Smith GW, Van Metre DC. Adjunctive flunixin meglumine therapy in calves with acute coccidiosis. J Vet Intern Med. 2003;17(2):199-204.

[49] Abu-Madi MA, Al-Ahdal MN, Taha ZS. Development of a live attenuated vaccine against bovine coccidiosis. Vaccine. 2012;30(18):2875-2882.

[50] Jenkins MC, O'Brien CN, Fetterer RH. Recombinant Eimeria antigens as vaccine candidates for cattle. J Parasitol. 1995;81(6):937-943.